NCT02006485View on ClinicalTrials.gov

Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

December 13, 2013

Primary Completion Date

October 31, 2019

Study Completion Date

October 31, 2019

Conditions
Chronic Lymphocytic LeukemiaNon-Hodgkin's Lymphoma
Interventions
DRUG

Ublituximab + TGR-1202

Ublituximab IV infusion TGR-1202 oral daily dose

DRUG

Ublituximab + TGR-1202 + ibrutinib

Ublituximab IV infusion TGR-1202 oral daily dose Ibrutinib oral daily dose

DRUG

Ublituximab + TGR-1202 + bendamustine

Ublituximab IV infusion TGR-1202 oral daily dose Bendamustine IV infusion

Trial Locations (6)

30322

TG Therapeutics Investigational Trial Site, Atlanta

35805

TG Therapeutics Investigational Trial Site, Huntsville

68198

TG Therapeutics Investigational Trial Site, Omaha

72401

TG Therapeutics Investigational Trial Site, Jonesboro

77030

MD Anderson Cancer Center, Houston

91010

TG Therapeutics Investigational Trial Site, Duarte

All Listed Sponsors
lead

TG Therapeutics, Inc.

INDUSTRY

NCT02006485 - Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies | Biotech Hunter | Biotech Hunter